期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 127, 期 4, 页码 1202-1214出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI88894
关键词
-
资金
- European Genomic Institute for Diabetes [ANR-10-LABX-46]
- European Commission [FP7-305707]
- Fondation de France
- Fondation pour la Recherche Medicale [DEQ20150331724]
Peroxisome proliferator-activated receptors (PPARs) regulate energy metabolism and hence are therapeutic targets in metabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease. While they share anti-inflammatory activities, the PPAR isotypes distinguish themselves by differential actions on lipid and glucose homeostasis. In this Review we discuss the complementary and distinct metabolic effects of the PPAR isotypes together with the underlying cellular and molecular mechanisms, as well as the synthetic PPAR ligands that are used in the clinic or under development. We highlight the potential of new PPAR ligands with improved efficacy and safety profiles in the treatment of complex metabolic disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据